Top Industry Leaders in the Insulinoma Market
Latest Insulinoma Treatment Companies Update:
Ipsen Pharma acquired Synta Pharmaceuticals, gaining access to their lead investigational drug for insulinoma, SOM230. This signifies Ipsen's commitment to expanding their presence in the insulinoma treatment market.
Johnson & Johnson partnered with University of California, San Diego, to develop novel therapies for pancreatic neuroendocrine tumors (NETs), which include insulinomas. This collaboration leverages J&J's expertise in drug development with UCSD's research strengths in NETs.
Teva Pharmaceuticals received FDA approval for lanreotide acetate injection (Somatuline Depot), a long-acting somatostatin analog, for the treatment of acromegaly and insulinoma. This expands Teva's portfolio of NET treatment options.
Novartis launched Lutathera® (lutetium Lu 177 dotatate) in the US, a radiopharmaceutical therapy for patients with inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including insulinomas. This offers a new treatment option for advanced cases.
List of Insulinoma Treatment companies in the market
- Abcam plc
- cironpharma
- Pfizer Plc.
- Entax Medical
- Olympus
- Boston Scientific Corporation
- Medtronic
- Cook Medical
- Cook Medical, Inc